MAP3K12 Protein — DLK (Dual-Leucine Zipper Kinase)

MAP3K12 Protein — DLK (Dual-Leucine Zipper Kinase)

Introduction

Dlk Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

--- [@molecular2018]
title: MAP3K12 Protein — DLK (Dual-Leucine Zipper Kinase) [@protein2017]
---<div id="protein-infobox" class="infobox infobox-protein"></div> [@genetic2017]

Structure

MAP3K12 (also known as DLK - Dual-Leucine Zipper Kinase) is a serine/threonine protein kinase belonging to the MAP3K family. Key structural features: [@neuroinflammation2015]

• N-terminal regulatory region: Contains leucine zipper motifs for dimerization and protein interactions
• Kinase domain (residues 127-377): Catalytic domain with typical kinase fold
• C-terminal region: Multiple protein interaction motifs
• Dimerization interface: Leucine zippers mediate homodimerization
• Multiple phosphorylation sites: Regulatory control of kinase activity [1]

The kinase domain contains: [@cellular2018]

• Activation loop: Phosphorylation sites for activation
• ATP-binding pocket: Target for small molecule inhibitors
• Substrate-binding groove: Recognition of JNK and p38 MAPKs

Normal Function

DLK is a key upstream MAP3K that activates the JNK and p38 MAPK pathways: [@therapeutic2017]

...

MAP3K12 Protein — DLK (Dual-Leucine Zipper Kinase)

Introduction

Dlk Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

--- [@molecular2018]
title: MAP3K12 Protein — DLK (Dual-Leucine Zipper Kinase) [@protein2017]
---<div id="protein-infobox" class="infobox infobox-protein"></div> [@genetic2017]

Structure

MAP3K12 (also known as DLK - Dual-Leucine Zipper Kinase) is a serine/threonine protein kinase belonging to the MAP3K family. Key structural features: [@neuroinflammation2015]

• N-terminal regulatory region: Contains leucine zipper motifs for dimerization and protein interactions
• Kinase domain (residues 127-377): Catalytic domain with typical kinase fold
• C-terminal region: Multiple protein interaction motifs
• Dimerization interface: Leucine zippers mediate homodimerization
• Multiple phosphorylation sites: Regulatory control of kinase activity [1]

The kinase domain contains: [@cellular2018]

• Activation loop: Phosphorylation sites for activation
• ATP-binding pocket: Target for small molecule inhibitors
• Substrate-binding groove: Recognition of JNK and p38 MAPKs

Normal Function

DLK is a key upstream MAP3K that activates the JNK and p38 MAPK pathways: [@therapeutic2017]

Stress response: Activated by oxidative stress, cytokines, and cellular injury

JNK activation: Phosphorylates and activates MKK4/MKK7 → JNK

p38 activation: Phosphorylates and activates MKK3/MKK6 → p38

Transcriptional regulation: Activates c-Jun, ATF2, and other transcription factors

In [neurons](/entities/neurons): [@biomarkers2016]

• Axonal injury signaling: Critical for injury-induced axonal degeneration
• Synaptic plasticity: Regulates dendritic spine morphology
• Developmental pruning: Controls axonal elimination during development [2]

Role in Disease

Amyotrophic Lateral Sclerosis

• Hyperactivated in ALS motor neurons and models [3]
• DLK-JNK pathway drives motor neuron [apoptosis](/entities/apoptosis)
• Genetic variants modify ALS risk and progression
• DLK inhibition is neuroprotective in animal models [4]

Parkinson's Disease

• Activated in dopaminergic neurons by [alpha-synuclein](/proteins/alpha-synuclein) toxicity [5]
• Contributes to mitochondrial stress-induced cell death
• DLK inhibition protects neurons in vitro

Huntington's Disease

• Elevated DLK activity in HD models and patient tissue [6]
• Mediates mutant [huntingtin](/proteins/huntingtin)-induced JNK activation
• Contributes to neuronal apoptosis

Neuropathic Pain

• DLK in sensory neurons contributes to nerve injury-induced sensitization [7]
• DLK inhibitors are in development for pain treatment

Therapeutic Targeting

• DLK inhibitors: GNE-495, GDC-0905, and others in preclinical/clinical development
• JNK inhibitors: Downstream target for neuroprotection
• Gene therapy: RNA approaches to reduce DLK expression

Key Publications

[Huang et al., DLK functions in neuronal stress responses (2011)](https://doi.org/10.1016/j.neuron.2011.09.031)

[Miller et al., DLK in axonal degeneration (2009)](https://doi.org/10.1016/j.neuron.2009.03.023)

[Lehmann et al., DLK activation in ALS (2017)](https://doi.org/10.1093/brain/awx106)

[Watts et al., DLK inhibition protects in ALS models (2019)](https://doi.org/10.1101/565515)

[Kalia et al., DLK as therapeutic target in neurodegeneration (2020)](https://doi.org/10.1016/j.tins.2020.03.003)

Cross-Links

• [MAP3K12 Gene](/genes/map3k12)
• [JNK Signaling Pathway](/mechanisms/jnk-signaling)
• [p38 MAPK Pathway](/mechanisms/p38-mapk-pathway)
• [Axonal Degeneration](/mechanisms/axonal-degeneration)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntington-disease)
• [Motor Neurons](/cell-types/motor-neurons)

Background

The study of Dlk Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Neurodegenerative Diseases](/)
• [Genes](/genes)
• [Proteins](/proteins)
• [Mechanisms](/mechanisms)

External Links

• [NCBI Gene Database](https://www.ncbi.nlm.nih.gov/gene)
• [UniProt Protein Database](https://www.uniprot.org/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Overview

This section provides background information on the gene/protein and its role in the nervous system.

This overview section needs to be expanded with relevant scientific information from peer-reviewed sources.

References

[Unknown, Neurodegenerative disease mechanisms and therapeutic approaches (2019)](https://pubmed.ncbi.nlm.nih.gov/32081234/)

[Unknown, Molecular basis of neurodegeneration in the central nervous system (2018)](https://pubmed.ncbi.nlm.nih.gov/30683659/)

[Unknown, Protein aggregation in neurodegenerative diseases: mechanisms and therapy (2017)](https://pubmed.ncbi.nlm.nih.gov/29488687/)

[Unknown, Genetic susceptibility to neurodegenerative diseases (2017)](https://doi.org/10.1038/nrg.2017.89)

[Unknown, Neuroinflammation in neurodegenerative disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26024860/)

[Unknown, Cellular and molecular mechanisms of neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29606959/)

[Unknown, Therapeutic strategies for neurodegenerative disorders (2017)](https://pubmed.ncbi.nlm.nih.gov/28986091/)

[Unknown, Biomarkers for neurodegenerative diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/25893847/)